Premium
Switching from one infliximab biosimilar (CT‐P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis
Author(s) -
Gisondi P.,
Virga C.,
Piaserico S.,
Meneguzzo A.,
Odorici G.,
Conti A.,
Girolomoni G.
Publication year - 2020
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19013
Subject(s) - biosimilar , infliximab , medicine , plaque psoriasis , psoriasis , dermatology , tumor necrosis factor alpha
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom